• SARS-CoV-2 Antigens for Diagnostic Uses & Immunisations

Assay Development, Immunisations & Vaccine Development

Nordic SARS Response is an enabling service and immunoassay reagent and vaccine antigen component provider. The company was founded by medical and biotech professionals with a wish to contribute to the collective societal fight against SARS-CoV-2. Using state of the art mammalian cell based expression technologies developed for biopharmaceutical production, we manufacture relevant SARS-CoV2 spike protein antigens in stable CHO-S and HEK293 suspension cultures.

The goal is to support serological assay providers and vaccine development in the Nordic region, Europe and US. Creating tools that make a difference in COVID-19 research, testing and diagnostics.

Serodiagnostics of covid-19

View the performance of our antigens in serodiagnostics of covid-19 patients. Jalkanen et al., Journal of Infectious Diseases, 2021

View

Variants and vaccine boosters?

We quantified the neutralisation capacity of the original wuhan strain vaccines against variants of SARS-CoV-2 and also noted in our data the weakened neutralisation capacity of the current vaccines against the beta variant. This is also of particular concern regarding animal reservoirs for the virus, that are in close proximity to humans and society. It is generally well know that the beta variant is able to infect a wider range of animals than was originally observed and expected in the beginning of the pandemic. This emphasises the need for larger animal vaccination campaigns, to strengthen current pandemic efforts, and booster shots for humanity, to gain better protection against virus variant infections and disease.

Article

Follow COVID-19 in real time

You can follow the spread of the pandemic in the link below. The map is updated in real time, with data sources such as the WHO and other governmental agencies’ reports.

Real Time Map

Lock and key

The Spike protein with its Receptor Binding Domain, RBD works like lock and key when binding to cell surface receptors such as ACE2 to initiate viral entry into cells. We have therefore chosen to concentrated much focus on this key interaction, as antibodies against the RBD, blocking the ACE2 interaction can be considered neutralising. In serological and vaccine research, hACE2 and RBD reagents can be used to mimic this interaction in what is known as a ”surrogate neutralisation assay” which can be used instead of a live virus neutralisation assay that requires a BSL-3 grade laboratory, to determine the neutralising quality of an elicited antibody response.

SARS-CoV2 Antigens

Contact to place larger orders

Contact us to know more about our products and services, to place a bulk order or to gain a licens to our technologies through a licensing agreement: Contact@SARSresponse.com

MORE